دورية أكاديمية
Venglustat, Lanreotide Acetate, and Tolvaptan as therapeutic options for the treatment of autosomic dominant polychistic kidney disease: a narrative review ; Venglustat, Acetato de Lanreotida y Tolvaptan como opciones terapéuticas para el tratamiento de la enfermedad renal poliquística autosómica dominante: revisión narrativa
| العنوان: | Venglustat, Lanreotide Acetate, and Tolvaptan as therapeutic options for the treatment of autosomic dominant polychistic kidney disease: a narrative review ; Venglustat, Acetato de Lanreotida y Tolvaptan como opciones terapéuticas para el tratamiento de la enfermedad renal poliquística autosómica dominante: revisión narrativa |
|---|---|
| المؤلفون: | Valencia Quintero, Juan Sebastian, Castillo, Diana |
| المصدر: | Interdisciplinary Journal of Epidemiology and Public Health; Vol. 3 No. 2 (2020); e-7246 ; Interdisciplinary Journal of Epidemiology and Public Health; Vol. 3 Núm. 2 (2020); e-7246 ; 2665-427X |
| بيانات النشر: | Universidad Libre |
| سنة النشر: | 2021 |
| المجموعة: | Portal de Revistas de la Universidad Libre Colombia |
| مصطلحات موضوعية: | enfermedad poliquística renal autosómica dominante, ADPKD, enfermedad poliquística renal, Tolvaptan, antagonistas receptores V2, Venglustat, inhibidor de la glucosilceramida sintasa, acetato de lanreotida, análogo de somatostatina, Autosomal dominant polycystic kidney disease, polycystic kidney disease, V2 receptor antagonists, glucosylceramide synthase inhibitor, lanreotide acetate, somatostatin analog |
| الوصف: | Introduction: autosomal polycystic kidney disease (ADPKD) is a hereditary orphan disease, with an average world prevalence of 2.7 per 100,000 inhabitants. Until recently, treatment was limited to the control of clinical manifestations, but since 2015 with the appearance of tolvaptan, the disease has been managed and the introduction of venglustat and lanreotide acetate as treatment makes it necessary to review therapeutic options. Methods: narrative review in PubMed, Cochrane Library, OVID, EBSCO and Google Scholar. Results: Were obtained 92 articles in the search strategy, of which five were included in the qualitative analysis. The TEMPO 3: 4 Study showed that tolvaptan reduced the annual growth rate in the total kidney volume from 5.5% to 2.8% (p <0.001), reducing the deterioration of the filtration rate. Glomerular tissue estimated at −3.70 to −2.72 mL/min/1.73 m2 (p <0.001) compared to placebo. THE DIPAK 1: evidence that lanreotide reduces kidney volume compared to placebo (4.15% vs. 5.56%; per year; 95% CI: -2.41% to -0.24%; p= 0.02). Venglustat clinical trials showed preliminary improvement in the annualized rate of change in total kidney volume (TKV) and estimated glomerular filtration rate (eGFR), according to the results of preclinical studies, however, they are still in study. Conclusions: ADPKD is a pathology with few therapeutic options and with recent treatments incorporated, currently under investigation. This article sets the guide for future study design quantitative. ; Introducción: la enfermedad poliquística renal autosómica (ADPKD), es considerada huérfana hereditaria. Con una prevalencia mundial de 2.7/100,000 hab. Presenta graves complicaciones con desenlaces fatales. Hasta hace poco, el tratamiento se limitó al control de las manifestaciones clínicas; con la aparición del tolvaptan, se empezó a manejar la enfermedad. La introducción terapéutica del inhibidor de glucosilceramida sintetasa (venglustat) y el acetato de lanreotida hacen necesario revisar el estado de estas opciones ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Spanish; Castilian |
| العلاقة: | https://revistas.unilibre.edu.co/index.php/iJEPH/article/view/7246/6441Test; https://revistas.unilibre.edu.co/index.php/iJEPH/article/view/7246Test |
| DOI: | 10.18041/2665-427X/ijeph.2.7246 |
| الإتاحة: | https://doi.org/10.18041/2665-427X/ijeph.2.7246Test https://revistas.unilibre.edu.co/index.php/iJEPH/article/view/7246Test |
| حقوق: | Derechos de autor 2020 Interdisciplinary Journal of Epidemiology and Public Health ; http://creativecommons.org/licenses/by-nc-nd/4.0Test |
| رقم الانضمام: | edsbas.B3D9737F |
| قاعدة البيانات: | BASE |
| DOI: | 10.18041/2665-427X/ijeph.2.7246 |
|---|